Navigation Links
Vanda Pharmaceuticals Reports First Quarter 2009 Results
Date:4/29/2009

le securities as of

March 31, 2009 totaled approximately $42.6 million, compared to

approximately $46.5 million as of December 31, 2008.

* Net loss for the first quarter of 2009 was $6.5 million, compared to

a net loss of $7.5 million for the fourth quarter of 2008 and a net

loss of $19.2 million for the first quarter of 2008.

* Net loss per common share for the first quarter of 2009 was $0.24,

compared to $0.28 for the fourth quarter of 2008 and $0.72 for the

first quarter of 2008.

FINANCIAL GUIDANCE

Vanda will update its financial guidance following the decision by the FDA regarding the New Drug Application for iloperidone.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
2. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
3. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
6. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
8. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
9. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
10. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)..., NEW YORK, Nov. 18 Reportlinker...s available in its catalogue. ,, Biotechnolog... http://www.reportlinker.com/p0164375/Biotechnolog...source=prnewswire&utm_medium=pr&utm_campai...gy are complex chemical compounds used in a range ...
(Date:11/18/2009)... Promega Corporation and SwitchGear G... DNA-protein interactions. , ...Promega Corporation and SwitchGear Genomics announ...nteractions. Results of a study using the HaloCHIP... demonstrate the ability to correlate DNA binding ...
(Date:11/18/2009)...VT-111 significantly reduces key cardiac enzymes a... presented at American Heart Association 2009 Scie...wire/ - Viron Therapeutics Inc., a biotechnology c...ting protein therapeutics derived from pathogens, ...rial evaluating VT-111 (Serp-1), an anti-inflammat...
(Date:11/18/2009)..., BALTIMORE, Nov. 18 Ch...CSBR), an oncology drug development company with a...ting the development and enhancing the value of on...ng agreement with Yale University and Southern Res...or cancer treatment. Scientists from Yale and Sou...
Breaking Biology Technology:Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 2Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 3Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 4Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 5Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 6Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 7Reportlinker Adds Biotechnology Reagents - A Global Market Perspective 8Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 2Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 3Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients 4Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 2Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 3Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology 4
...SEY CITY, New Jersey, October 29, Rosetta Genomics... of microRNA-based diagnostics, announced today it...al Healthcare Conference,taking place November 3-4...ty., About MicroRNA, MicroRNAs (miRNAs) are rece...hat act as master regulators and have the potentia...
.... 29 Osteotech, Inc.,(Nasdaq: OSTE ), a leader i...enerative healing, announced today that it has rec... and Drug Administration ("FDA") for its next,gene...) clearance for this,material as a bone graft subs...spine, pelvis and extremities., Sam Owusu-Akyaw, ...
...Arena Pharmaceuticals,Inc. (Nasdaq: ARNA ) announ... at the Oppenheimer 19th Annual Healthcare Confere...5:40 a.m. Pacific Time) at the,Waldorf=Astoria Hot...ce,President, Finance and Chief Financial Officer,...y, including its clinical development and discover...
Other Biology Technology:Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Osteotech Receives FDA Clearance for its Next Generation Grafting Material 2Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 2Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference 3
(Date:11/20/2009)... ANN ARBOR, Mich.---We,ve all read studies about t...ame thing is true at the molecular level, where am...ble to damage when single than when paired up with...ersity of Michigan, along with colleagues in Belgi...protects single cysteines. The research appears in...
(Date:11/20/2009)..., A key question in the origin of biological mol...ether billions of years ago from simple precursors...searchers in Italy have reconstructed one of the e...ains of RNA from individual subunits using nothing...t RNA was one of the first biological molecules pr...
(Date:11/20/2009)... This release is available in German . , I...ical Investigation , Dr. Stefanie Eyerich and Dr. ... Imperial College London and Istituto Dermopatico ...ing discovery. It represents a milestone on the wa...tory skin diseases such as psoriasis and allergic ...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Should noninvasive ventilation be considered a high risk procedure during an epidemic 3F 59338 1Should noninvasive ventilation be considered a high risk procedure during an epidemic 3F 59338 2ADSC 26apos 3Bs Pain Management Reinforcement 59333 1ADSC 26apos 3Bs Pain Management Reinforcement 59333 2Dry Skin and Eczema May Be Reduced with New Toxic Substances Control Act 59328 1Dry Skin and Eczema May Be Reduced with New Toxic Substances Control Act 59328 2
...s, cells in your eye are transmitting information ...ies work just as hard to keep that brain alive. Ev...e body -- depends on an internal process called en...nd information healthy and strong. , It,s an incre...at Weill Medical College of Cornell University in ...
... packaging. How nature wraps and tags genes determ...researchers from Harvard and the Massachusetts Ins...t, most detailed study to date of the protein stru...dings reveal surprising and previously unknown spe...ment of the human body and in diseases such as can...
...t growing older are as,inevitable and obvious as “...lain the precise cause of this usually unwelcome t... site of the journal Science,researchers from Dan...Boston say they have found the cellular cause of g...ignant melanoma, the potentially deadly,skin cance...
Other Biology News:Weill Cornell Research Reveals Secrets Of Trafficking Within Cells 2Weill Cornell Research Reveals Secrets Of Trafficking Within Cells 3Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease 2Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease 3Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery 2Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery 3
SPoT-Light EGFR Probe from Invitrogen
Human Skeletal Muscle RACE-Ready cDNA from Ambion
CCF4-AM from Invitrogen
CCF4-AM from Invitrogen
Biology Products: